Menu

Search

  |   Business

Menu

  |   Business

Search

Faraday Pharmaceuticals Announces First-In-Human Trial of FDY-5301

SEATTLE - Faraday Pharmaceuticals, a biopharmaceutical company focused on the development of elemental reducing agents for critical care medicine, today announced the start of a Phase 1 clinical trial evaluating its lead compound FDY-5301.

The randomized, double blind, placebo-controlled trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single, escalating, intravenous doses of FDY-5301 versus placebo in healthy volunteers. FDY-5301 contains elemental iodine in its reduced form – iodide – formulated for intravenous administration.

Preclinical data have demonstrated the ability of FDY-5301 to diminish reperfusion injury in both cardiac and skeletal muscle in a range of different animal models and in multiple species. The Phase 1 trial is being conducted in Australia and is targeted to enroll approximately 40 subjects.

"It's gratifying to begin this first-in-human study following the promising preclinical findings to date, and less than six months after our initial 'GLP' toxicity studies were initiated. Our elemental reducing agents have demonstrated compelling activity in a number of animal studies, including models of cardiac reperfusion, radiation injury and organ transplantation," said Stephen A. Hill, M.D., Chief Executive Officer of Faraday. "We are working hard on our Phase 2 preparations in hope of providing new options to patients as expeditiously as possible."

Faraday Pharmaceuticals is a biopharmaceutical company focused on the research and development of elemental reducing agents (ERAs). These therapeutic agents have potential applications for treatment of critical care illnesses. The company is headquartered in Seattle. 

  • ET PRO
  • Market Data

Market-moving news and views, 24 hours a day >

January 19 15:30 UTC Released

USECRI Weekly Annualized

Actual

4.5 %

Forecast

Previous

3.3 %

January 19 15:30 UTC Released

USECRI Weekly Index

Actual

150.3 %

Forecast

Previous

147.6 %

January 21 21:00 UTC 10031003m

KRPPI Growth YY

Actual

Forecast

Previous

3.1 %

January 21 21:00 UTC 10031003m

KRPPI Growth

Actual

Forecast

Previous

-0.1 %

January 21 23:00 UTC 11231123m

JPReuters Tankan DI

Actual

Forecast

Previous

27 k

January 22 07:00 UTC 16031603m

NOIndus Confidence

Actual

Forecast

Previous

2 0

January 22 08:00 UTC 16631663m

TWJobless Rate

Actual

Forecast

Previous

3.69 0

January 22 08:00 UTC 16631663m

TWExport Orders YY

Actual

Forecast

Previous

11.6 0

January 22 09:00 UTC 17231723m

GRCbank C/A YY

Actual

Forecast

Previous

-0.624 0

January 22 13:30 UTC 19931993m

USNational Activity Index

Actual

Forecast

Previous

0.15 %

Close

Welcome to EconoTimes

Sign up for daily updates for the most important
stories unfolding in the global economy.